PRIMOR- sulfadimethoxine and ormetoprim tablet

Pajjiż: Stati Uniti

Lingwa: Ingliż

Sors: NLM (National Library of Medicine)

Ingredjent attiv:

sulfadimethoxine (UNII: 30CPC5LDEX) (sulfadimethoxine - UNII:30CPC5LDEX), ormetoprim (UNII: M3EFS94984) (ormetoprim - UNII:M3EFS94984)

Disponibbli minn:

Zoetis Inc.

INN (Isem Internazzjonali):

sulfadimethoxine

Kompożizzjoni:

sulfadimethoxine 100 mg

Rotta amministrattiva:

ORAL

Tip ta 'preskrizzjoni:

PRESCRIPTION

Indikazzjonijiet terapewtiċi:

Primor is for the treatment of skin and soft tissue infections (wounds and abscesses) in dogs caused by strains of Staphylococcus aureus and Escherichia coli and urinary tract infections caused by Escherichia coli, Staphylococcus spp., and Proteus mirabilis susceptible to sulfadimethoxine/ormetoprim. Primor should not be used in dogs showing marked liver parenchymal damage, blood dyscrasias, or in those with a history of sulfonamide hypersensitivity.

Sommarju tal-prodott:

Primor is available as scored tablets for the following potencies: 120 mg, 240 mg, 600 mg, and 1200 mg.

L-istatus ta 'awtorizzazzjoni:

New Animal Drug Application

Karatteristiċi tal-prodott

PRIMOR- SULFADIMETHOXINE AND ORMETOPRIM TABLET
ZOETIS INC.
----------
PRIMOR
(SULFADIMETHOXINE/ORMETOPRIM)
TABLETS
CAUTION
Federal law restricts this drug to use by or on the order of a
licensed veterinarian.
DESCRIPTION
Primor is an antimicrobial drug containing sulfadimethoxine and
ormetoprim in a 5 to 1
ratio. The combination of these 2 compounds results in the
potentiation of
sulfadimethoxine, providing increased efficacy, a broadened spectrum
of activity to
include some sulfonamide-resistant organisms, and reduction in the
rate of resistance
development.
Sulfadimethoxine is a white, almost tasteless and odorless powder.
Chemically, it is N -
(2,6-dimethoxy-4-pyrimidinyl)-sulfanila-mide. The structural formula
is:
Ormetoprim is a white, almost tasteless powder. Chemically, it is
2,4-diamino-5-(4,5-
dimethoxy-2-methylbenzyl)-pyrimidine. The structural formula is:
®
1
CLINICAL PHARMACOLOGY
Sulfadimethoxine is not acetylated in the dog, as in most other
animals, and is excreted
predominantly as the unchanged drug.
Sulfadimethoxine has a relatively high solubility
at the pH normally occurring in the kidney, precluding the possibility
of precipitation and
crystalluria. Slow renal excretion results from a high degree of
tubular reabsorption.
Plasma protein binding is very high, providing a blood reservoir of
the drug. Thus
sulfadimethoxine maintains higher blood levels than most other
long-acting
sulfonamides. Single, comparatively low doses of sulfadimethoxine give
rapid and
sustained therapeutic blood levels.
The systemically active sulfonamides, which include sulfadimethoxine,
are bacteriostatic
agents. Sulfonamides competitively inhibit bacterial synthesis of
folic acid
(pteroylglutamic acid) from para-aminobenzoic acid. Mammalian cells
are capable of
utilizing folic acid in the presence of sulfonamides.
Ormetoprim, like other diaminopyrimidines, inhibits the reduction of
dihydrofolic acid to
tetrahydrofolic acid by bacterial cells.
Sulfadimethoxine/ormetoprim thus blocks 2 sequential steps of the
folic acid m